Abstract
Nevirapine (viramune) is a nonnucleoside reverse transcriptase inhibitor commonly used in combination with other antiretroviral medicines in the treatment of HIV/AIDS. The safety profile of nevirapine, as determined by review of prospective clinical trials, reports rash with an incidence of 16% as the most common side effect. Clinical hepatitis is reported to occur with an incidence of 1%. A review of the literature shows many case reports of nevirapine-induced hepatotoxicity in patients receiving both treatment and prophylaxis for HIV. The purpose of this case report is to stress the importance of early recognition and withdrawal of the offending drug.
Recommended Citation
Baichi, Matt
(2003)
"Nevirapine Hepatotoxicity: Case Report and Discussion,"
The Medicine Forum: Vol. 4, Article 6.
DOI: https://doi.org/10.29046/TMF.004.1.007
Available at:
https://jdc.jefferson.edu/tmf/vol4/iss1/6
